Showing results (131-140 of 199) with videos related to

Sort By:
Pageof 20
Oncotarget|June 9, 2016
Direct contact with perivascular tumor cells enhances integrin αvβ3 signaling and migration of endothelial cellsMonica E Burgett, Justin D Lathia, Patrick Roth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2013
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant gliomaDavid A Reardon, Morris D Groves, Patrick Y Wen, et al.
Neuro-Oncology|May 27, 2015
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastomaElizabeth R Gerstner, Xiaobu Ye, Dan G Duda, et al.
Neuro-Oncology|November 19, 2010
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumabMichael Prados, Timothy Cloughesy, Meghna Samant, et al.
Journal of the American Medical Informatics Association : JAMIA|January 27, 2012
Integrated morphologic analysis for the identification and characterization of disease subtypesLee A D Cooper, Jun Kong, David A Gutman, et al.
Plos One|April 27, 2012
DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastomaStefanie Galbán, Benjamin Lemasson, Terence M Williams, et al.
Neoplasia (New York, N.Y.)|August 14, 2014
Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapyGregory J Baker, Viveka Nand Yadav, Sebastien Motsch, et al.
Genome Research|October 3, 2007
Altered adenosine-to-inosine RNA editing in human cancerNurit Paz, Erez Y Levanon, Ninette Amariglio, et al.
Cancer Reports (Hoboken, N.J.)|May 20, 2021
Rapid real-world data analysis of patients with cancer, with and without COVID-19, across distinct health systemsClara Hwang, Monika A Izano, Michael A Thompson, et al.
Neuro-Oncology|March 13, 2015
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE studyL Burt Nabors, Karen L Fink, Tom Mikkelsen, et al.
Pageof 20